269 related articles for article (PubMed ID: 32245391)
1. Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report.
Nishino K; Kunimasa K; Kimura M; Inoue T; Tamiya M; Kuhara H; Kumagai T
BMC Pharmacol Toxicol; 2020 Apr; 21(1):26. PubMed ID: 32245391
[TBL] [Abstract][Full Text] [Related]
2. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.
Yorozuya T; Taya T; Yasuda K; Nagano Y; Shioya M; Chiba H; Takahashi H
Thorac Cancer; 2020 Apr; 11(4):1090-1093. PubMed ID: 32045109
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Wadsworth C; Melillo G; Jiang H; Huang Y; Dennis PA; Özgüroğlu M;
N Engl J Med; 2017 Nov; 377(20):1919-1929. PubMed ID: 28885881
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
9. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
10. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
[TBL] [Abstract][Full Text] [Related]
11. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer.
Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
14. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.
Cheema PK; Rothenstein J; Melosky B; Brade A; Hirsh V
Curr Oncol; 2019 Feb; 26(1):37-42. PubMed ID: 30853796
[TBL] [Abstract][Full Text] [Related]
15. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
16. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
17. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
18. Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
Takahashi T; Tateishi A; Bychkov A; Fukuoka J
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130676
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
20. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N; Bar J; Garrido P; Garassino MC; McDonald F; Mornex F; Filippi AR; Smit HJM; Peters S; Field JK; Christoph DC; Sibille A; Fietkau R; Haakensen VD; Chouaid C; Markman B; Hiltermann TJN; Taus A; Sawyer W; Allen A; Chander P; Licour M; Solomon B
J Thorac Oncol; 2023 Feb; 18(2):181-193. PubMed ID: 36307040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]